Editorial

What Happens When Drug Development Becomes Modular?
Editorial What Happens When Drug Development Becomes Modular?

The biopharmaceutical industry is entering its modular era. Drug development no longer operates with singular, siloed breakthroughs, but rather thrives on systems that are reused, reconfigured, and simulated. From plug-and-play manufacturing redefining flexibility to digital twins transforming

De-Risking Biologics Through Early Assessment Tools
Editorial De-Risking Biologics Through Early Assessment Tools

Predicting how a biotherapeutic will behave in humans is a critical step in drug design —but it's far from straightforward. While nonclinical models can help foresee certain negative effects, they often fall short when it comes to immunotoxicity and other immune-related reactions. With the growing

5 Breakthroughs Now Revolutionizing Drug Development
Editorial 5 Breakthroughs Now Revolutionizing Drug Development

Technology and science are constantly evolving and advancing, and with them, the world of drug development is also changing. Using AI and CRISPR for gene editing and bioprinting human-like tissues are just some examples of innovations that are set to change how life-saving therapies are developed.

Gene Therapy is Here to Change Everything
Editorial Gene Therapy is Here to Change Everything

The biopharmaceutical industry is undergoing rapid transformation due to the rising popularity of cell and gene therapy for various cancer conditions, some uncommon diseases, and degenerative conditions, as traditional drugs and biological products show limited success. The field is now moving to

2025 Biotech Survival Guide: The 5 Key Threats You Can’t Ignore
Editorial 2025 Biotech Survival Guide: The 5 Key Threats You Can’t Ignore

The biotech industry in particular will experience high levels of uncertainty and changes in 2025. Emerging biotech companies are facing significant challenges due to new technologies, intense global competition, and changes in the market. Next year, 2025, may be tough for startups as they

Building the Future: Why Biopharma Campuses Must Evolve
Editorial Building the Future: Why Biopharma Campuses Must Evolve

The life sciences industry has come a long way since the last COVID-19 outbreak. Today, organizations are prioritizing efficiency, speed, and innovation. That’s why biopharma and biotech companies are increasingly broadening their investments in physical spaces. Campuses and facilities are being

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later